Semin Arthritis Rheu:银屑病关节炎疾病影响问卷的新作用

2019-04-21 xiangting MedSci原创

最小疾病活动度(MDA)使用健康评估问卷(HAQ)作为一个标准。随着PsA病程的增加,HAQ与疾病活动性的相关性不佳,并且其在MDA中的应用受到质疑。银屑病关节炎疾病影响(PsAID)是专为PsA患者开发的。这项研究目的是在患者队列中验证PsAID,并确定在MDA中PsAID是否可以取代HAQ。从PsA诊所招募患者,并根据标准方案进行评估,其中包括人口学、临床特征和实验室检查。进行描述性统计。基于

最小疾病活动度(MDA)使用健康评估问卷(HAQ)作为一个标准。随着PsA病程的增加,HAQ与疾病活动性的相关性不佳,并且其在MDA中的应用受到质疑。银屑病关节炎疾病影响(PsAID)是专为PsA患者开发的。这项研究目的是在患者队列中验证PsAID,并确定在MDA中PsAID是否可以取代HAQ。

从PsA诊所招募患者,并根据标准方案进行评估,其中包括人口学、临床特征和实验室检查。进行描述性统计。基于银屑病关节炎临床疾病活动性(cDAPSA)产生用于MDA的PsAID阈值。

115例患者完成了PsAID。男性70例,女性45例,平均PsA病程为18.7年(±11.6)。PsAID-9和PsAID-12的平均评分分别为3.4(±2.4)和3.2(±2.3)。PsAID与临床施用的9种PROMs中度相关性良好(ρ= 0.51-0.78)。产生了基于cDAPSA的4个PsAID阈值用于MDA:缓解(REM)PsAID-9、REM PsAID-12、低疾病活动性(LDA)PsAID-9和LDA PsAID-12。所有4种版本的PsAID MDAs对HAQ-MDA的敏感性均大于85%,而3种版本的PsAID-MDAs对HAQ-MDA的特异性大于85%。

PsAID-MDA对HAQ-MDA的敏感性和特异性高表明PsAID是MDA中HAQ的有效替代。

原始出处:
Kishor Johnson.  A NOVEL ROLE FOR PSORIATIC ARTHRITIS IMPACT OF DISEASE QUESTIONNAIRE (PsAID). Semin Arthritis Rheu. 19 April 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924142, encodeId=d03e192414250, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Aug 26 15:15:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972635, encodeId=4e4a19e263501, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Mar 11 22:15:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365229, encodeId=1cab365229b8, content=学习推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Thu Apr 25 09:44:28 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265951, encodeId=14a01265951cd, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357168, encodeId=55a2135e168fb, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924142, encodeId=d03e192414250, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Aug 26 15:15:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972635, encodeId=4e4a19e263501, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Mar 11 22:15:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365229, encodeId=1cab365229b8, content=学习推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Thu Apr 25 09:44:28 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265951, encodeId=14a01265951cd, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357168, encodeId=55a2135e168fb, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1924142, encodeId=d03e192414250, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Aug 26 15:15:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972635, encodeId=4e4a19e263501, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Mar 11 22:15:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365229, encodeId=1cab365229b8, content=学习推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Thu Apr 25 09:44:28 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265951, encodeId=14a01265951cd, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357168, encodeId=55a2135e168fb, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
    2019-04-25 gcwu82

    学习推荐

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1924142, encodeId=d03e192414250, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Aug 26 15:15:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972635, encodeId=4e4a19e263501, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Mar 11 22:15:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365229, encodeId=1cab365229b8, content=学习推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Thu Apr 25 09:44:28 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265951, encodeId=14a01265951cd, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357168, encodeId=55a2135e168fb, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
    2019-04-23 lmm397
  5. [GetPortalCommentsPageByObjectIdResponse(id=1924142, encodeId=d03e192414250, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Aug 26 15:15:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972635, encodeId=4e4a19e263501, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Mar 11 22:15:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365229, encodeId=1cab365229b8, content=学习推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Thu Apr 25 09:44:28 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265951, encodeId=14a01265951cd, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357168, encodeId=55a2135e168fb, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Apr 23 02:15:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
    2019-04-23 zhaojie88

相关资讯

J Rheumatol:银屑病关节炎患者使用TNFi达到缓解的预测因子

根据CDAI标准,基于美国的登记中少数PsA患者达到缓解。女性、肥胖、合并症和教育程度对使用TNFi能否达到缓解有影响。

J Rheumatol:银屑病关节炎患者的负担和疾病特征

不同严重程度PsA患者的疾病负担都很明显。相当一部分PsA患者未接受过抗银屑病治疗。

Arthritis Rheumatol:依那西普和甲氨蝶呤单药或联合用药治疗银屑病关节炎的疗效

联合甲氨蝶呤和依那西普并未改善依那西普的疗效。

Ann Rheum Dis:早期使用TNF抑制剂有助于银屑病关节炎的缓解

在早期PsA患者中,第22周戈利木单抗+MTX的DAS缓解率几乎是单用MTX的2倍。

J Rheumatol:使用生物制剂治疗银屑病关节炎的指炎和附着点炎

汇总分析表明,抗TNF-α药物与新型药物(ustekinumab、苏金单抗和ixekizumab)在指炎和附着点炎上具有相同疗效。